{"id":"W3093864427","doi":"10.1016/j.jaci.2020.10.015","title":"Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial","year":2020,"lang":"en","type":"article","venue":"Journal of Allergy and Clinical Immunology","topic":"Coagulation, Bradykinin, Polyphosphates, and Angioedema","field":"Medicine","cited_by":163,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Ottawa; Ottawa Allergy Research Corporation","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institutes of Health; BioCryst; Ionis Pharmaceuticals; Regeneron Pharmaceuticals; Sanofi; AstraZeneca; Aimmune Therapeutics; CSL Behring; Harvard Catalyst; GlaxoSmithKline; Genentech","keywords":"Medicine; Hereditary angioedema; Placebo; Tolerability; Adverse effect; Nausea; Vomiting; Randomized controlled trial; Abdominal pain; Internal medicine; Clinical endpoint; Angioedema; Diarrhea; Anesthesia; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002189472,0.001429909,0.003083013,0.0004026383,0.0006115699,0.001121394,0.0008486211,0.001927097,0.008044378],"category_scores_gemma":[0.001621006,0.0006217216,0.001561429,0.0003864482,0.001084511,0.0009529885,0.0003407396,0.002123377,0.0010029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005903055,"about_ca_system_score_gemma":0.001454925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007296699,"about_ca_topic_score_gemma":0.001598155,"domain_scores_codex":[0.9991886,0.00040485,0.00004732966,0.0001531137,0.00008214531,0.0001239343],"domain_scores_gemma":[0.9990168,0.0002375018,0.0002511024,0.00007794831,0.00008682653,0.0003299002],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9795065,0.005921491,0.0004262959,0.0007995637,0.0006186097,0.00004610989,0.00004113625,0.0001487754,0.002236794,0.00008794777,0.0009025809,0.009264206],"study_design_scores_gemma":[0.9816865,0.01704112,0.0005925192,0.00001673737,0.0001398784,0.00001665131,0.000006092014,0.0001194344,0.0001038072,0.00004377036,0.0002285266,0.000005076456],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9695033,0.008109434,0.001288804,0.001185053,0.0009213674,0.01316406,0.002227498,0.0003325911,0.003267898],"genre_scores_gemma":[0.971945,0.004497223,0.002527751,0.002163789,0.0006984555,0.01304679,0.001505355,0.00004379679,0.003571736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008044378,"threshold_uncertainty_score":0.0269112,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09577189653942489,"score_gpt":0.4001914682474612,"score_spread":0.3044195717080362,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}